Checklist
Asia Peptide Verification (APV) — buyer-side diligence
Semaglutide COA red flags for buyers
A semaglutide COA should help a buyer decide whether the batch evidence is usable.
If the document creates more ambiguity than clarity, that is itself a red flag.
Use this when
You have a semaglutide COA in hand and need to know whether it supports the supplier story or just looks polished.
1) Batch identity should be clear
- Batch identifiers, dates, and material name should be specific.
- The COA should line up with the quote, invoice, and supplier identity.
- Generic or recycled-looking batch details are a warning sign.
2) Purity language should be usable
- Purity claims should be attached to a real batch, not just marketing language.
- The document should be readable enough to ask sensible follow-up questions.
- If the purity claim matters to the decision, the buyer may still need deeper verification.
3) Entity mismatches matter
- The company on the COA, website, and commercial documents should reconcile.
- If the supplier cannot explain which entity produced the material, the document is weaker.
- Manufacturer-vs-trader ambiguity is a common COA context problem.
4) A polished PDF is not enough
- Layout quality does not substitute for procurement relevance.
- The buyer still needs to know who made the material and how the claim fits the order.
- If the COA leaves major gaps, document review alone may not be enough.